R&D channel feed

CSL shares down 5% af­ter post-heart at­tack drug dis­ap­points in late-stage test

Last year

Cor­rec­tion: Iambic says new AI mod­el bests Al­phaFold as pro­tein mod­els rock­et ahead

Last year
AI

CSL and uniQure un­veil three-year da­ta for one-time he­mo­phil­ia B gene ther­a­py that costs $3.5M

Last year
Pharma
Cell/Gene Tx

Syn­log­ic reach­es end of the road for syn­thet­ic bi­ol­o­gy quest af­ter piv­otal da­ta dis­ap­point

Last year
People

Madri­gal re­ports new safe­ty da­ta for NASH can­di­date resme­tirom weeks ahead of PDU­FA date

Last year

Re­genxbio to seek ac­cel­er­at­ed ap­proval of Hunter syn­drome gene ther­a­py us­ing bio­mark­er da­ta

Last year
Cell/Gene Tx

An eye-drop ver­sion of Krys­tal Biotech's skin gene ther­a­py helped re­store vi­sion of boy with rare dis­ease

Last year
Cell/Gene Tx

Gilead stops last PhI­II of CD47 drug, cit­ing FDA hold, high­er risk of death in treat­ment arm

Last year

De­nali touts more bio­mark­er da­ta with ac­cel­er­at­ed ap­proval in mind

Last year

In a snap­shot of its rare dis­ease da­ta, Ul­tragenyx boosts case for new sur­ro­gate bio­mark­er

Last year
Cell/Gene Tx

Lil­ly ax­es PhI­II tri­al of Verzenio in prostate can­cer

Last year
Pharma

Up­dat­ed: Lil­ly re­ports mid-stage win for tirzepatide in fat­ty liv­er dis­ease MASH

Last year

GSK de­tails Blenrep’s PhI­II com­bo win as it hopes to stage a turn­around in mul­ti­ple myelo­ma

Last year

J&J touts suc­cess of Vyv­gart com­peti­tor in two au­toim­mune dis­ease tri­als, in­clud­ing key myas­the­nia gravis study

Last year

Pli­ant’s chron­ic liv­er dis­ease drug has con­sis­tent safe­ty across dose ranges, PhII da­ta show

Last year

Am­gen en­ters weight loss mar­ket with drug that shows 14.5% weight re­duc­tion

Last year

4D Mol­e­c­u­lar Ther­a­peu­tic­s' gene ther­a­py cuts Eylea use in wet AMD pa­tients, biotech di­vulges plans for piv­otal stud­ies

Last year
Cell/Gene Tx

Re­al Hu­mi­ra com­pe­ti­tion may not ar­rive un­til 2026, Ab­b­Vie ex­ecs tell in­vestors

Last year
Pharma

Re­gen­eron aims to stop mus­cle loss with com­bi­na­tion treat­ment ap­proach in obe­si­ty

Last year
Pharma

Take­da says farewell to CFO, suite of clin­i­cal-stage pro­grams in Q3 up­date

Last year
Pharma

Schrödinger takes a step for­ward with Al­phaFold in drug R&D, as biotech hits a pipeline 'in­flec­tion'

Last year
AI

‘120 pages of da­ta’: Roche’s pipeline re­view leads to as­set cuts, but al­so ad­di­tions

Last year
Pharma

‘Watch this evolve’: Sanofi con­tin­ues to talk up its R&D bet as Paul Hud­son wel­comes new CFO

Last year
Pharma

Apoc­a­lypse or rip­ple? Ahead of first of­fers on price, new re­search pre­dicts IRA im­pact on R&D will be mod­est

Last year
FDA+
First page Previous page 55565758596061 Next page Last page
A service from the Financial Times